Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/Op18 to Pak1-WAVE2-kinesin complex.

Takahashi K, Suzuki K.

Cell Signal. 2009 May;21(5):695-703. doi: 10.1016/j.cellsig.2009.01.007. Epub 2009 Jan 7.

PMID:
19162178
2.

Targeting group II PAKs in cancer and metastasis.

Eswaran J, Soundararajan M, Knapp S.

Cancer Metastasis Rev. 2009 Jun;28(1-2):209-17. doi: 10.1007/s10555-008-9181-4. Review.

PMID:
19160016
3.

p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics.

Allen JD, Jaffer ZM, Park SJ, Burgin S, Hofmann C, Sells MA, Chen S, Derr-Yellin E, Michels EG, McDaniel A, Bessler WK, Ingram DA, Atkinson SJ, Travers JB, Chernoff J, Clapp DW.

Blood. 2009 Mar 19;113(12):2695-705. doi: 10.1182/blood-2008-06-160861. Epub 2009 Jan 5.

4.

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.

Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, Fry DW, Zhu T, Loi CM, Fakhoury SA, Schlosser KM, Sexton KE, Winters RT, Reed JE, Bridges AJ, Lettiere DJ, Baker DA, Yang J, Lee HT, Tecle H, Vincent PW.

Mol Cancer Ther. 2008 Jul;7(7):1880-9. doi: 10.1158/1535-7163.MCT-07-2232. Epub 2008 Jul 7.

5.

Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.

Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO.

Cancer Res. 2008 Jul 1;68(13):5236-45. doi: 10.1158/0008-5472.CAN-07-5849.

6.

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.

Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.

Chem Biol. 2008 May;15(5):459-66. doi: 10.1016/j.chembiol.2008.03.013.

7.

An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR.

Chem Biol. 2008 Apr;15(4):322-31. doi: 10.1016/j.chembiol.2008.03.005.

8.

Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling.

Koh W, Mahan RD, Davis GE.

J Cell Sci. 2008 Apr 1;121(Pt 7):989-1001. doi: 10.1242/jcs.020693. Epub 2008 Mar 4.

9.

The Rac1 polybasic region is required for interaction with its effector PRK1.

Modha R, Campbell LJ, Nietlispach D, Buhecha HR, Owen D, Mott HR.

J Biol Chem. 2008 Jan 18;283(3):1492-500. Epub 2007 Nov 15.

10.

Specificity profiling of Pak kinases allows identification of novel phosphorylation sites.

Rennefahrt UE, Deacon SW, Parker SA, Devarajan K, Beeser A, Chernoff J, Knapp S, Turk BE, Peterson JR.

J Biol Chem. 2007 May 25;282(21):15667-78. Epub 2007 Mar 28.

11.

Covalent reactions of wortmannin under physiological conditions.

Yuan H, Barnes KR, Weissleder R, Cantley L, Josephson L.

Chem Biol. 2007 Mar;14(3):321-8.

12.

Get off my back! Rapid receptor internalization through circular dorsal ruffles.

Orth JD, McNiven MA.

Cancer Res. 2006 Dec 1;66(23):11094-6. Review.

13.

Drug-target residence time and its implications for lead optimization.

Copeland RA, Pompliano DL, Meek TD.

Nat Rev Drug Discov. 2006 Sep;5(9):730-9. Epub 2006 Aug 4. Review. Erratum in: Nat Rev Drug Discov. 2007 Mar;6(3):249.

PMID:
16888652
14.

p21-activated kinases in cancer.

Kumar R, Gururaj AE, Barnes CJ.

Nat Rev Cancer. 2006 Jun;6(6):459-71. Review.

PMID:
16723992
15.
16.

Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

Schirmer A, Kennedy J, Murli S, Reid R, Santi DV.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4234-9. Epub 2006 Mar 6.

17.

Foot and mouth: podosomes, invadopodia and circular dorsal ruffles.

Buccione R, Orth JD, McNiven MA.

Nat Rev Mol Cell Biol. 2004 Aug;5(8):647-57. Review.

PMID:
15366708
18.

p21-activated kinase 1: an emerging therapeutic target.

Vadlamudi RK, Kumar R.

Cancer Treat Res. 2004;119:77-88. Review. No abstract available.

PMID:
15164874
19.

P21-activated kinases in human cancer.

Vadlamudi RK, Kumar R.

Cancer Metastasis Rev. 2003 Dec;22(4):385-93. Review.

PMID:
12884913
20.

Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1.

Parrini MC, Lei M, Harrison SC, Mayer BJ.

Mol Cell. 2002 Jan;9(1):73-83.

Supplemental Content

Support Center